Itranols (Itraconazole)

Itraconazole is an azole antifungal used to manage systemic and localized fungal diseases.

• Blastomycosis: eradicates the infection and reduces risk of relapse.
• Histoplasmosis: clears the organism from affected tissues and prevents dissemination.
• Aspergillosis: controls invasive disease and improves survival in at‑risk patients.
• Candidiasis (oropharyngeal and esophageal): relieves symptoms and eliminates Candida overgrowth.
• Dermatophytosis: treats skin and nail infections caused by dermatophytes.
• Sporotrichosis: resolves cutaneous and lymphocutaneous disease.

• Itraconazole inhibits the fungal enzyme lanosterol 14α‑demethylase, a cytochrome P450 isoform essential for converting lanosterol to ergosterol. By blocking ergosterol synthesis, the drug disrupts the fungal cell membrane structure and function, leading to increased membrane permeability and inhibition of fungal growth.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild stomach upset occurring early in therapy.
• Headache: transient headache reported by some patients.
• Abdominal pain: discomfort or cramping in the gastrointestinal tract.
• Rash: mild skin erythema or itching.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or hepatitis requiring monitoring.
• Cardiac failure: rare cases of congestive heart failure, especially in patients with pre‑existing heart disease.
• Severe hypersensitivity: anaphylactic reactions or Stevens‑Johnson syndrome.

When prescribing itraconazole, clinicians should consider several safety measures to minimize risk.

• Liver function monitoring: assess baseline enzymes and repeat during therapy.
• Drug‑interaction review: avoid concomitant use with strong CYP3A4 inhibitors or inducers.
• Cardiac assessment: evaluate for existing heart failure before initiating treatment.
• Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited.
• Patient counseling: advise on adherence, possible side effects, and need for regular follow‑up.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Itraconazole interacts with several medicines through CYP3A4 modulation and other pathways.

Major Interactions (Avoid)

• Ketoconazole: combined use may cause severe hepatotoxicity.
• Rifampicin: potent inducer reduces itraconazole exposure, compromising efficacy.
• Certain statins (e.g., simvastatin): increased risk of myopathy and rhabdomyolysis.
• HIV protease inhibitors (e.g., ritonavir): can lead to toxic itraconazole levels.
• Ergot derivatives: heightened risk of ergotism due to elevated plasma concentrations.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers (e.g., amlodipine): may require dose adjustment.
• Benzodiazepines (e.g., midazolam): increased sedation, monitor effect.
• Anticoagulants (e.g., warfarin): possible alteration of INR, monitor coagulation.
• Oral contraceptives: reduced efficacy, advise backup contraception.
• Antacids containing aluminum or magnesium: may decrease absorption, separate dosing by at least 2 hours.